|
The digitization of clinical trials marks a pivotal moment in drug development, offering the potential to make studies more patient-centred, inclusive, and efficient. When thoughtfully implemented, digital technologies can break down long-standing barriers, empower patients as true partners in research, and accelerate the delivery of life-saving therapies, according to a study.
By combining operational innovation with a steadfast focus on patient welfare, equity, and trust, all the concerned stakeholders can achieve this objective and lower barriers to participation, and expand diversity and inclusion in clinical trials, the study adds.
Digital technology integration ranges from the incorporation of artificial intelligence in diagnostic devices to the use of real-world data (e.g., electronic health records) for study recruitment. Clinical trials can now be conducted entirely virtually, eliminating the need for in-person interaction.
Digital technology is driving efficiency in clinical trials. Since the traditional clinical trial process is often time-consuming and costly, digital health technologies are driving efficiency, opine some experts.
As India is emerging as a hub for clinical trials, thanks to its large, diverse population, Indian clinical research companies are increasingly adopting high-tech solutions to enhance patient recruitment and improve outcome predictions. By leveraging advanced technologies such as artificial intelligence, machine learning, and big data analytics, these companies can target patient recruitment and machine learning models can forecast outcomes by analyzing historical data, helping researchers assess the likely success of clinical trials and optimize study designs.
Artificial intelligence and machine learning are being used to streamline patient recruitment, identify suitable candidates based on health data, and predict outcomes more accurately. Moreover, decentralized trials, enabled by remote monitoring tools, allow broader participation, reduce geographic barriers, and speed up the process, according to Nandita Saini, associate vice president, engineering, GlobalLogic.
As the country grapples with challenges of access, affordability, and infrastructure, innovative digital health solutions are emerging as game-changers poised to reshape the healthcare ecosystem. We recognize the pivotal role technology plays in addressing these challenges and unlocking new possibilities for enhanced patient outcomes, remote care, and more efficient clinical trials, Saini said.
Our country’s healthcare landscape is complex, characterized by a vast urban-rural divide in access to care, a shortage of medical professionals, and varying degrees of infrastructure readiness. Moreover, affordability remains a significant concern for most of the population. Yet, the integration of digital technologies like telemedicine, artificial intelligence and big data analytics is offering solutions to these pressing challenges, she said.
Even as telemedicine has gained significant traction, the AI-driven chatbots and virtual assistants enhance patient interactions, provide initial diagnostics, and offer advice, thereby reducing the load on healthcare professionals. AI can identify trends and predict potential health risks by analyzing vast amounts of patient data. For example, AI tools are being used to detect early signs of diseases such as diabetes and cardiovascular conditions, which are prevalent in India. Additionally, AI-driven diagnostic tools reduce the time needed for medical imaging analysis, enhance accuracy, and make critical diagnostic services more widely accessible, said Saini.
Big data analytics is also crucial in personalized medicine. By using genetic and lifestyle data, clinicians can develop more targeted and effective treatment plans tailored to individual patients, addressing a major gap in the one-size-fits-all approach to treatment.
The ability to provide remote care is not just a convenience but a necessity in a country where nearly 70 per cent of the population resides in rural areas. Mobile health (mHealth) applications, telehealth platforms, and connected devices are enabling healthcare providers to monitor patients’ conditions in real-time, reducing the need for frequent hospital visits and allowing for timely interventions. This shift is especially critical in managing chronic diseases, where ongoing monitoring is key to preventing complications. The integration of wearable technologies is further enhancing patient outcomes.
Looking forward, we see several emerging trends that will further shape the future of healthcare in India. AI-driven diagnostics will continue to evolve, offering even more precise and rapid analysis. Wearable tech will become more sophisticated, providing continuous monitoring and enabling predictive healthcare. Additionally, personalized medicine will become more widespread, leveraging AI and genetic data to tailor treatments to individual patients, said Saini adding that GlobalLogic too is ensuring that these advancements are not only accessible but also transformative for the Indian healthcare ecosystem.
Novel technologies reshaping clinical trial landscape
Adoption of novel technologies like virtual and decentralized trials, artificial intelligence (AI), and real-world data are reshaping the India’s clinical trials landscape, said Sanjay Vyas, executive vice president and managing director, Parexel.
Decentralized trials are leveraging digital technologies to enhance patient access and participation, enabling remote monitoring, telemedicine consultations, and electronic consent processes, he added.
There is an increasing focus on oncology clinical trials due to rising cancer prevalence and the need for innovative therapies. Also, private hospital networks are diversifying into tier 2/3 cities, providing broad access to patients, he said.
The geopolitical landscape is shifting in a way that could make India an increasingly attractive destination for pharmaceutical companies and researchers worldwide. Government initiatives like the Foreign Direct Investment (FDI) and production linked incentive (PLI) plan are creating opportunities for India, Vyas said.
India has emerged as a significant player in the global clinical trials landscape, with its market valued at US$ 2.05 billion in 2024 and projected to grow at a compound annual growth rate (CAGR) of 8.64 per cent through 2030. This growth is fuelled by several factors that make India an attractive destination for pharmaceutical companies and researchers worldwide. The vast and diverse patient population provides an ideal environment for clinical research. The demographic diversity allows for more comprehensive and representative studies, improving the generalizability of results. Additionally, the country’s cost-effective operational environment and large pool of skilled medical professionals contribute significantly to its appeal. The pool of potential participants also makes India an attractive destination for various therapeutic areas, particularly oncology, diabetes, and infectious diseases, he noted.
There is significant growth in phase 2 and 3 trials which are growing 15-18 per cent annually. There is also a growing prevalence of lifestyle diseases like diabetes and cardiovascular diseases driving demand for clinical trials. Regulatory advancements through amendments to the New Drugs and Clinical Trials (NDCT) Rules in 2019 are streamlining approval processes and introducing compensation provisions.
|